Cerca
Ara mostrant els elements 1-6 de 6
Clinical significance of indeterminate quantiFERON-TB Gold plus assay results in hospitalized COVID-19 patients with severe hyperinflammatory syndrome
(MDPI, 2021)
Performance of the QuantiFERON-TB Gold Plus (QFT-Plus) assay could be affected by conditions of immune dysregulation. Little is known about the reliability of QTF-Plus in COVID-19 patients. Our aim was ...
Risk categories in COVID-19 based on degrees of inflammation: data on more than 17,000 patients from the spanish SEMI-COVID-19 registry
(MDPI, 2021)
(1) Background: The inflammation or cytokine storm that accompanies COVID-19 marks the prognosis. This study aimed to identify three risk categories based on inflammatory parameters on admission. (2) ...
Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19
(Frontiers Media S.A., 2021)
Introduction: Loss-of-function TLR7 variants have been recently reported in a small number of males to underlie strong predisposition to severe COVID-19. We aimed to determine the presence of these rare ...
Methylprednisolone pulses plus tacrolimus in addition to standard of care vs. standard of care alone in patients with severe COVID-19. A randomized controlled trial
(Frontiers Media, 2021)
Introduction: Severe lung injury is triggered by both the SARS-CoV-2 infection and the subsequent host-immune response in some COVID-19 patients. Methods: We conducted a randomized, single-center, ...
High-dose methylprednisolone pulses for 3 days vs. low-dose dexamethasone for 10 days in severe, non-critical COVID-19: a retrospective propensity score matched analysis
(MDPI, 2021)
Corticosteroids are largely recommended in patients with severe COVID-19. However, evidence to support high-dose methylprednisolone (MP) pulses is not as robust as that demonstrated for low-dose ...
Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: the TACROVID trial protocol
(Elsevier, 2021-03)
Introduction: Some COVID-19 patients evolve to severe lung injury and systemic hyperinflammatory syndrome triggered by both the coronavirus infection and the subsequent host-immune response. Accordingly, ...